tbuckley/cabot-search huggingface dataset:
An extrarenal source of "renin-like" activity in anephric man.
Authors: Weinberger Mh, Wade Mb, Aoi W, Usa T, Dentino M, Luft F, Grim Ce
Journal: Circulation Research (1977)

To examine extrarenal sources of  activity plasma was obtained from 19 anephric males. Plasma renin activity (PRA), concentration (PRC) (obtained after addition of exogenous renin substrate) and total renin concentration (TRC) (obtained after acid-activation of plasma and subsequent incubation with exogenous renin substrate) demonstrated values for several anephric patients comparable or above those seen in plasma from 10 normal subjects. Incubation of untreated plasma (PRA and PRC) and acid-dialyzed plasma (TRC) for angiotensin I generation was performed at pH 7.5, at 37 degrees C with EDTA, dimercaprol, and 8-OH-quinoline as angiotensinase and converting enzyme inhibitors. The pH optimum for acid-activation of TRC in anephric plasma was the same as that in normal plasma (pH 3.3). Molecular weight determinations following Sephadex gel chromatography demonstrated that the renin-like enzyme in normal plasma had a molecular weight of about 42,000 before and after acid-activation, while that in anephric plasma had a molecular weight of approximately 61,000. A saliva sample from one anephric subject with the highest levels of PRA, PRC, and TRC in plasma also demonstrated measurable amounts of PRA, PRC, and TRC. The molecular weight of this salivary  activity also was 61,000. These observations suggest a possible extrarenal source of  activity in anephric man. The physiological significance of these studies remains to be clarified.
Clinically Undiagnosed Tuberculosis in Large General Hospital
Authors: J M HOLLISTER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease
Authors: Maria Fusaro, Sandro Giannini, Maurizio Gallieni
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The American Psychiatric Association and the Food and Drug Administration: an analysis and proposal for action
Authors: R Dorsey
Journal: American Journal of Psychiatry (1978)

The relationship between medicine and society is currently undergoing substantial change. While the Food and Drug Administration has no legal authority over the practicing physician, its decisions already influence medical practice. The Drug Regulation Reform Act of 1978, if passed in its present form, would grant FDA broad new powers over patient care and clinical research. In order to retain a high degree of control of its future and activities, the American Psychiatric Association must develop an effective mechanism for meeting this challenge and for serving the interests of its members and their patients. Dr. Alexander M. Schmidt comments on the author's presentation.
PTU-170 Fibulin-5 expression in the skin of patients with rectal prolapse
Authors: HM Joshi, I Lindsey, C Cunningham, J Urban, O Jones
Journal: Gut (2015)

<h3>Introduction</h3> Rectal prolapse is a prevalent disorder affecting up to 10% of patients in the United Kingdom. Components of the connective tissue other than collagen have been found to be involved in development of prolapse. Elastic fibre organisation differs between controls and subsets of patients with rectal prolapse. Transgenic mice have demonstrated the importance of elastic fibres for maintaining structural and functional integrity of the pelvic floor. Elastic fibres assembly is a complex process and fibulin-5 integral in this process. Mice with null mutation in fibulin-5 (<i>Fbln5</i>¡<i>/</i>¡) develop a prolapse that is remarkably similar to that of primates. <h3>Method</h3> Between January 2013 and February 2014, skin specimens were obtained prospectively during surgery from 20 patients with rectal prolapse and from 21 patients without prolapse undergoing surgery for other indications. Fibroblasts from the skin were cultured and levels of Fibulin -5 expression was determined on cultured fibroblasts, isolated from these specimens by Quantitative Real-Time PCR. Immunohistochemistry was performed on fixed tissue specimens to assess FIB-5 expression. <h3>Results</h3> FIB-5 mRNA expression and FIB-5 staining intensity was significantly lower in the young male patients with rectal prolapse when compared to age matched control groups. (FIB-5 mean +/- SD mRNA relative units) 1.1 +/- 0.41 vs. 0.53 +/- 0.22, p = 0.001] and Intensity score, median (range), 2 (0–3) vs. 1 (0–3), p = 0.05]. There was no significant differences in expression of FIB-5 in women with rectal prolapse compared with control. <h3>Conclusion</h3> FIB-5 maybe implicated in the aetiology of rectal prolapse in a subgroup of young male patients. <h3>Disclosure of interest</h3> None Declared.
Relationship between estimated premorbid adjustment and CSF homovanillic acid and 5-hydroxyindoleacetic acid levels
Authors: J F Leckman, M B Bowers, J S Sturges
Journal: American Journal of Psychiatry (1981)

The authors completed ratings of premorbid sexual and social adjustment and assays of the CSF homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and probenecid concentrations in 108 psychiatric patients. Among the 30 patients diagnosed as schizophrenic, poor premorbid sexual adjustment was associated with higher accumulations of HVA in the CSF. No relationship between the estimated premorbid social adjustment and CSF HVA levels was observed. These findings suggest that 1) sexual and social premorbid adjustment are partially independent variables, and 2) one of the biological correlates of sexual adjustment in schizophrenic patients may be the functional maturity of central dopamine systems.
A pseudo-outbreak of human A/H5N1 infections in Greece and its public health implications
Authors: G Spala, T Panagiotopoulos, N Mavroidi, X Dedoukou, A Baka, P Tsonou, E Triantafyllou, A Mentis, V Kyriazopoulou, A Melidou, S Tsiodras
Journal: Eurosurveillance (2006)

The recent wide geographic spread of the highly pathogenic avian influenza A/H5N1 virus has important public health implications. Several wild migratory birds were confirmed to be infected with avian influenza A/H5N1 in Greece in February and March 2006. The aim of this paper is to report data from potential H5N1 human cases that presented to local hospitals during this period with a respiratory infection and expressing concern about exposure to avian influenza. A case-control investigation was conducted that included case identification with the use of a structured definition, review of epidemiological and clinical characteristics and molecular testing for avian influenza A/H5N1. The setting was the entire country of Greece during February and March 2006. The main outcomes were rates of possible cases (meeting both a clinical and an epidemiological criterion) and clinical or epidemiological characteristics differentiating them from potential cases that met either one of the criteria of a possible case, but not both. Twenty six potential patients (81% of whom met a clinical criterion, and 39% of whom met an epidemiological criterion) presented and most (85%) were admitted in local hospitals during the period of interest. The majority of cases (85%) were observed in northern Greece where most of the confirmed A/H5N1 avian cases were documented. Five of the 26 evaluated patients met the definition of a possible case. These clustered within the early period of confirmed A/H5N1 cases in wild migratory birds (P=0.05). Molecular testing was negative for all possible cases. Application of a revised case definition constructed according to newer European Union guidance resulted in the exclusion of two possible cases. Several potential A/H5N1 human cases were recently identified in Greece. Both the timing of identification and the geographical location of potential cases suggest an increased awareness on the part of the general public, as well as poor interpretation of the case definition by the clinicians.
Suppression of Tumors and Transplants of Fetal Digestive Tract Growing in Newborn Mice
Authors: Bella G. Tumyan, Svetlana N. Zinzar, George J. Svet-Moldavsky, Bertha I. Leitina
Journal: JNCI Journal of the National Cancer Institute (1974)

Transplants of different sections of fetal digestive tract (DT) grew progressively and formed huge organ-like cysts in all adult BALB/c syngeneic recipients. The histologic structure of these cysts was similar to that of corresponding sections of the gastrointestinal tract. Some of these cysts underwent spontaneous malignant conversion 13–16 months later: Adenocarcinomas of the small and large intestines, solid epithelial tumors, and sarcomas or leiomyosarcomas developed. Transplantable strains were obtained from these tumors. The growth of organ-like cysts, formed from fetal DT, was markedly retarded in the newborn recipients as compared with that in adults. Stomach and large-intestine cysts appeared in 100% of the newborn mice, but they grew much more slowly than the cysts in the adult recipients. Cysts from fetal small-intestine transplants appeared later and developed only in 43–47% of the newborn recipients, as compared with 100% of the adults. Growth of transplantable tumors of DT was significantly retarded in newborn recipients as compared with that in adults. The greatest difference in tumor growth in newborns and adults occurred in transplantation of the small-intestine adenocarcinoma. It is assumed that newborn mice have certain nonimmunologic properties that specifically influence the growth of transplants and tumors of DT, particularly tumors of the small intestine.
PTU-212 A systematic review of bioabsorbable synthetic anal fistula plug for treatment of cryptoglandular fistula in ano
Authors: SK Narang, C Jones, N Alam, S Pathak, I Daniels, N Smart
Journal: Gut (2015)

<h3>Introduction</h3> Damage to the anal sphincter musculature during treatment of fistula in ano is a dreaded complication. Absorbable synthetic fistula plug have been used as a novel sphincter saving technique. The aim of this systematic review was to review the literature and assess the effectiveness of absorbable synthetic fistula plug for treatment of cryptoglandular fistula in ano. <h3>Method</h3> A systematic review of all English language literature relevant to fistula plug treatment of cryptoglandular fistula in ano, published between 1 January 2010 and 15 February 2015 was carried out using MEDLINE, EMBASE and the Cochrane Library of Systematic Reviews/Controlled Trials for relevant literature. Relevant articles were identified, quality assessed using the MINORS criteria and the data were extracted by two researchers independently. The identified articles were assessed with regards to fistula healing rate, duration of follow up and complication rates related to the use of bioabsorbable fistula plugs. <h3>Results</h3> A total of 26 potential articles were identified from the literature search. Using the predefined inclusion and exclusion criteria, 6 articles were included for the final analysis, data extraction and data synthesis. Of the 6 studies included in the review only 3 studies were prospective in study design. Complete data were available for 187 of the 221 patients who underwent this treatment. The age of the participants ranged from 19–82 years. The fistula healing rates were reported to be between 15.8% &gt;72.7% on follow up ranging from 2–19 months. Early or delayed plug extrusion occurred in 16 patients. A slight deterioration in continence was reported in 11 patients. <h3>Conclusion</h3> Synthetic bioabsorbable anal fistula plugs appears to be a simple and safe procedure associated with low complication rates and faecal incontinence. Given the significant heterogeneity in the study design, sample size and reported outcomes, further studies with longer follow up are needed. <h3>Disclosure of interest</h3> None Declared.
AB0423 Some Early Data of Anti-TNF Treatment in Patients with Chronic Kidney Disease and Rheumatoid Arthritis or Ankylosing Spondylitis: Largest Series in the Literature: Table 1
Authors: S. Şenel, K. Gök
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatoid arthritis (RA) and Ankylosing Spondylitis (AS) are the most common inflammatory rheumatic diseases. Comparing to healthy population, chronic kidney disease (CKD) might be more common in these patients due to complications such as amyloidosis or toxicity because of drug use. Anti-TNF treatment is an effective option in treatments of RA and AS.There is limited data whether anti-TNF treatment is efficient and safe in patients with RA or AS. We summarized some early data of 9 patients in this poster which was the largest serie in the literature. <h3>Objectives</h3> We analyzed our 9 CKD patients with RA or AS prospectively and aimed to evaluate efficacy and safety of anti-TNF treatment (infliksimab, etanercept, adalimumab, golimumab) in these patients. <h3>Methods</h3> AS patient met the New York Modified Criteria and RA was diagnosed according to the classification criteria of the 2010 ACR/ EULAR. Patients who are creatinine level ≥1.3 mg/dL accepted as CKD. We measured sedimentation and CRP levels in all patients, BASDAI score in AS patients and DAS28 score in RA patients during follow-up period. Adverse effects such as infection and allergic reactions were noted. <h3>Results</h3> We analyzed 3 RA and 6 AS patients with CKD due to amyloidosis (n=5), polycystic kidney disease (n=1), diabetic nephropathy (n=2), hypertension (n=1). Eight of patients were male and one patient was female. Two patients were under hemodialysis (Pateint 2, 5). Six patients received etanercept, one adalimumab, one golimumab and one infliksimab treatment. Six of patients took isoniazid prophylaxis. Only, Patient 1 was having leflunomid 20 mg/day and other synthetic DMARDs were not used in other patients. During follow up, DAS28 scores in RA patients and BASDAI scores in AS patients were decreased significantly and there were no increase in the scores. The efficacy data will publish in the future paper. The only adverse effect was a non-serious local allergic reaction was seen in patient 7. The detailed data was presented in Table 1. <h3>Conclusions</h3> As a result, anti-TNF treatment appears to be safe, well-tolerated and efficient in chronic kidney patients with RA and AS in our limited number of patients. Nonetheless, increased infection risk in CKD patients must be kept in mind. Future studies in larger population groups about efficacy or safety of anti-TNF treatment in CKD patients is required. <h3>References</h3> Senel S, Kisacik B, Ugan Y, Kasifoglu T, Tunc E, Cobankara V. The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol. 2011 Oct;30(10):1369-72. <h3>Disclosure of Interest</h3> None declared
In this series we ask one or more experts to review a case. They are provided with information on which further management is to be based, and asked to explain their rationale, using the available evidence in the literature. What was actually done in the case is then revealed. A Case of Severe Gallstone Pancreatitis
Authors: J. Baillie
Journal: Endoscopy (2000)

I am pleased to welcome as our Guest Discussant a former trainee of mine, and now a colleague, Dr Klaus Mergener, who is currently Chief of Endoscopy at the Johannes Gutenberg University Medical Clinic in Mainz, Germany. Dr Mergener developed a special interest in acute pancreatitis during his Advanced Endoscopy Fellowship at Duke University Medical Center, and has written a number of excellent papers and reviews on the subject. Welcome, Dr Mergener.
Brief Communication: Potentiation of an Adenovirus-Associated Virus by Herpes Simplex Virus Type-2-Transformed Cells2
Authors: Neil R. Blacklow
Journal: JNCI Journal of the National Cancer Institute (1975)

The herpes simplex virus type-2 (HSV-2)-transformed cell line 333-8-9 was inoculated with adeno-virus-associated virus type 3 (AAV-3) and examined by immunofluorescent (FA) techniques for evidence of AAV-3 antigen synthesis. Antisera prepared against the three sodium dodecyl sulfate-dissociated structural polypeptides (VP-1, VP-2, and VP-3) of AAV-3 and against the whole AAV-3 virion were used as probes to search for AAV-3 FA-stainable antigens synthesized by these cells. The 333-8-9 cells inoculated with AAV-3 ALONE PRODUCED FA-stainable antigens detected by VP-1, VP-3, and whole virion antisera, but not by the VP-2 antiserum. Coinfection of AAV-3-INOCULATED 333-8-9 CELLS WITH EITHER ADENOVIRUS TYPE-2 (Ad.2) or herpes simplex virus type-1 (HSV-1) helper permitted the formation of FA-stainable antigens detected by all antisera, including the VP-2 antiserum. In contrast to 333-8-9 cells, BHK-21 cells failed to produce AAV-3 FA-stainable antigens when inoculated with AAV-3 alone; addition of either Ad.2 or HSV-1 helper led to formation of antigens detected by all VP and whole virion antisera. These results suggest that 333-8-9 cells enhance the formation of two of the three AAV-3 structural polypeptides and that this incomplete potentiation may be related to HSV-2 genetic material possessed by these cells.
<i>Choroba Glodowa</i>
Authors: Jan R. Dmochowski, Francis D. Moore
Journal: New England Journal of Medicine (1975)

Scientific observations are often called into ethical question, when they are based on the study of sick and suffering people. This criticism remains true even though there have been many occasions when the study of the sick has brought help not only to future generations but to the patient under care. It is clear that under the most ideal circumstances, a conflict of interest remains: the temptation to exploit today's patient for future knowledge, must always be bridled by immediate concern for the patient's care.These difficulties of ethical policy are nowhere more evident than with the prisoner. His employment . . .
Ethics of Commercial Screening Tests
Authors: Erik A. Wallace, John H. Schumann, Steven E. Weinberger
Journal: Annals of Internal Medicine (2013)

Letters19 March 2013Ethics of Commercial Screening TestsErik A. Wallace, MD, John H. Schumann, MD, and Steven E. Weinberger, MDErik A. Wallace, MDFrom University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, and American College of Physicians, Philadelphia, Pennsylvania., John H. Schumann, MDFrom University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, and American College of Physicians, Philadelphia, Pennsylvania., and Steven E. Weinberger, MDFrom University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, and American College of Physicians, Philadelphia, Pennsylvania.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-6-201303190-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Keller correctly states that some of the tests offered by commercial screening companies can be obtained for less time and money than if they were ordered by a primary care physician during an office visit. However, through the Patient Protection and Affordable Care Act, some recommended preventive services (such as abdominal aortic ultrasonography in men aged 65 to 75 years who previously smoked) are required to be covered by health insurance plans with no cost-sharing by beneficiaries (1).In addition, it is important to note that the article's focus was not primarily on the costs or quality ...Reference1. Koh HK, Sebelius KG. Promoting prevention through the Affordable Care Act. N Engl J Med. 2010;363:1296-9. [PMID: 20879876] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Erik A. Wallace, MD; John H. Schumann, MD; Steven E. Weinberger, MDAffiliations: From University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, and American College of Physicians, Philadelphia, Pennsylvania.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0927. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEthics of Commercial Screening Tests Erik A. Wallace , John H. Schumann , and Steven E. Weinberger Ethics of Commercial Screening Tests David L. Keller Metrics Cited bySensor-as-a-Service: Convergence of Sensor Analytic Point Solutions (SNAPS) and Pay-A-Penny-Per-Use (PAPPU) Paradigm as a Catalyst for Democratization of Healthcare in Underserved Communities 19 March 2013Volume 158, Issue 6Page: 500KeywordsConflicts of interestDecision makingDisclosureHealth insurancePatient Protection and Affordable Care ActPopulation statisticsPrimary care physiciansUltrasound imaging ePublished: 19 March 2013 Issue Published: 19 March 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Decreased anterior cingulate gyrus metabolic rate in schizophrenia
Authors: M M Haznedar, M S Buchsbaum, C Luu, E A Hazlett, B V Siegel, J Lohr, J Wu, R J Haier, W E Bunney
Journal: American Journal of Psychiatry (1997)

This study examined glucose metabolism in the anterior and posterior cingulate cortex in schizophrenia.Fifty unmedicated male schizophrenic patients and 24 normal men were studied with positron emission tomography.Compared with the normal men, the schizophrenic patients had lower relative metabolic rates in the anterior cingulate and higher rates in the posterior cingulate.The findings suggest hypofunction in the anterior cingulate cortex in schizophrenia.